MicroRNAs may be implicated in the acquisition of drug resistance in CML as they regulate the expression of not only BCR-ABL1 but also genes associated with the activation of drug transfer proteins or essential signaling pathways (14, 15). Here, ABL1 is linked to chronic myelogenous leukemia, BCR-ABL1 positive.